Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukemia Clinical Trial

Official title:

A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00337246
• Other study ID #: CTRU-NCRI-UKCLL01-FCM/FCM-R
• Secondary ID: CDR0000485181EU-
• Status: Completed
• Phase: Phase 2
• First received: June 13, 2006
• Last updated: August 1, 2013
• Start date: July 2005
• Est. completion date: March 2011

Study information

• Verified date: May 2007
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with rituximab may kill more cancer cells. It is not yet known whether giving combination chemotherapy together with rituximab is more effective than combination chemotherapy alone in treating chronic lymphocytic leukemia.

PURPOSE: This randomized phase II trial is studying how well giving combination chemotherapy with or without rituximab works in treating patients with previously treated chronic lymphocytic leukemia.

Description:

OBJECTIVES:

Primary

• Assess the efficacy and safety of fludarabine, cyclophosphamide, and mitoxantrone hydrochloride with or without rituximab in patients with previously treated chronic lymphocytic leukemia.

• Determine the overall response rate, defined as complete or partial remission, in these patients.

Secondary

• Determine the proportion of patients with undetectable minimal residual disease.

• Determine the 2-year progression-free survival of these patients.

• Determine the 2-year overall survival of these patients.

• Determine the toxicity of this regimen.

OUTLINE: This is a randomized, controlled, open-label, parallel group, multicenter study. Patients are stratified according to prior treatment with fludarabine (refractory vs not refractory or naive). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral fludarabine* and oral cyclophosphamide* on days 1-5 and mitoxantrone hydrochloride IV on day 1.

• Arm II: Patients receive fludarabine*, cyclophosphamide*, and mitoxantrone hydrochloride as in arm I. Patients also receive rituximab IV on day 1.

NOTE: *If the oral regimen is not tolerated, patients may receive fludarabine IV and cyclophosphamide IV on days 1-3.

Treatment in both arms repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 3 years.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 56 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: March 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of chronic lymphocytic leukemia requiring therapy

• Previously treated with = 1 chemotherapeutic regimen

PATIENT CHARACTERISTICS:

• WHO performance status 0-2

• Life expectancy = 12 weeks

• Creatinine clearance = 30 mL/min

• Not pregnant or nursing

• Negative pregnancy test

• Fertile female patients must use effective contraception for 4 weeks before, during, and for 6 months after completion of study treatment

• Fertile male patients must use effective contraception during and for 6 months after completion of study treatment

• No history of anaphylaxis after exposure to rat or mouse-derived complementary-determining region (CDR)-grafted humanized monoclonal antibodies

• No toxicity attributable to purine analogues (e.g., autoimmune hemolytic anemia, neurological toxicity, or allergy)

• No active infection

• No other severe (particularly cardiac or pulmonary) diseases or mental disorders that would preclude study participation

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior fludarabine (or other purine analogues) combined with cyclophosphamide and mitoxantrone hydrochloride

• No prior rituximab, either alone or in combination with chemotherapy

Study Design

Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Biological:
• rituximab

Drug:
• cyclophosphamide

• fludarabine phosphate

• mitoxantrone hydrochloride

Locations

Country	Name	City	State
United Kingdom	Monklands General Hospital	Airdrie	Scotland
United Kingdom	Birmingham Heartlands Hospital	Birmingham	England
United Kingdom	Blackpool Victoria Hospital	Blackpool	England
United Kingdom	Kent and Canterbury Hospital	Canterbury	England
United Kingdom	University Hospital of Wales	Cardiff	Wales
United Kingdom	St Helier Hospital	Carshalton	England
United Kingdom	Darent Valley Hospital	Dartford Kent	England
United Kingdom	Medway Maritime Hospital	Gillingham Kent	England
United Kingdom	Leeds General Infirmary at Leeds Teaching Hospital NHS Trust	Leeds	England
United Kingdom	Leicester Royal Infirmary	Leicester	England
United Kingdom	Royal Liverpool and Broadgreen Hospitals NHS Trust	Liverpool	England
United Kingdom	Maidstone Hospital	Maidstone	England
United Kingdom	Christie Hospital NHS Trust	Manchester	England
United Kingdom	Royal Cornwall Hospital	Truro, Cornwall	England
United Kingdom	Kent and Sussex Hospital	Tunbridge Wells, Kent	England
United Kingdom	Wishaw General Hospital	Wishaw	England

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Research UK

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, Kennedy DB, Fegan C, Milligan DW, Radford J, Mercieca J, Dearden C, Ezekwisili R, Smith AF, Brown J, Booth GA, Varghese AM, Pocock C; NCRI CLL Sub-Group. A randomized phase II trial of fluda — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate as measured by NCI Response Criteria			No
Secondary	Proportion of patients with undetectable minimal residual disease			No
Secondary	Progression-free survival at 2 years			No
Secondary	Overall survival at 2 years			No
Secondary	Toxicity			Yes